Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012043 | 0.83 | DPP4 (0.42) | TAAR1HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4673127 | 0.81 | DPP4 (0.41) | TAAR1HTR2ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29167063 | 0.81 | SLC6A2 (0.42) | TAAR1SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL1162293 | 0.81 | LMNA (0.42) | SLC6A2SLC6A4SLC6A3DPP4F2 | |
| SCHEMBL20746075 | 0.81 | LMNA (0.42) | SLC6A2SLC6A4SLC6A3DPP4F2 | |
| SCHEMBL1355671 | 0.79 | — | — | |
| SCHEMBL8761844 | 0.79 | DPP4 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL8761852 | 0.79 | DPP4 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL1358135 | 0.79 | DPP4 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL17724513 | 0.78 | SCN4A (0.40) | TAAR1DPP4F2SCN4ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042293-B9 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1042293-B1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| CN-1328277-C | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1448564-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003044021-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | IL1A, IL1B, IL6 | TAAR1 1574/4885HTR2A 442/4885SLC6A2 2552/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | TAAR1 1612/4885HTR2A 1913/4885SLC6A2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.